Observational studyBioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy2024

Patient Satisfaction and Experience with CT-P17 Following Transition from Reference Adalimumab or Another Adalimumab Biosimilar: Results from the Real-World YU-MATTER Study.

Guillaume Bouguen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.